Investor Relations 2018-06-29T15:31:34+00:00

Predictive’s mission is to revolutionize the care of patients through novel gene-based diagnostics and companion therapeutics.  Our relentless questioning and persistence will assist in our endeavors to eliminate diseases in our generation and generations to come.

Business Description

Predictive Technology Group, Inc. (PRED) through its wholly owned subsidiary Predictive Therapeutics, Inc. revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company has developed and/or acquired a number of proprietary technologies that open a window into the origin of human disease and the role that genes and their related proteins play in the disease’s onset and progression. PRED uses this information as the cornerstone in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat the disease.

52 week Range -
/

Financial Reporting

Profile Data

Events and Webcasts

Corporate Governance

Service Proivders

Corporate Counsel / Intellectual PropertyWilson Sonsini Goodrich and Rosati
650 Page Mill Road
Palo Alto, CA 94304
1-650-493-9300
Investor RelationsLHA Investor Relations
2121 Avenue of the Stars, Suite 2970
Los Angeles, CA 90067
Jody Cain: Jcain@lhai.com
Kevin McCabe: KMcCabe@lhai.com
1-310-691-7100 ext 202 or 215
Predictive Science and SalesScience Advisory and Sales
2735 E. Parleys Way, Suite 205
Salt Lake City, UT 84109
Office: 1-888-407-2477
Fax: 1-801-487-2477

What’s Next, Now?

Revolutionizing patient care through novel gene-based companion diagnostics and therapeutics.

Contact Us